It is therefore tempting to speculate that sustained ERK5 signaling neutralizes the antiproliferative effect of anti-HER2 agents in resistant breast cancer cells by promoting RB phosphorylation through the cyclin E–associated CDK2 complex (Fig. 7D). The gene discussed is CDK2; the disease is breast carcinoma.